FRRS1L gene replacement ameliorates disease phenotypes in the mouse model of developmental and epileptic encephalopathy 37.
Gene therapy partially restores brain function in mice with a rare childhood epilepsy, offering the first hope for a condition with no approved treatment.
Intrathecal AAV9-mediated FRRS1L gene replacement in a DEE37 mouse model partially restores synaptic AMPA receptor abundance and achieves dose-dependent rescue of structural, electrocorticographic, and behavioral phenotypes. These results provide the first preclinical proof-of-concept for gene therapy in this rare pediatric epileptic encephalopathy with no existing approved treatment.
What the study was
- Study design
- preclinical gene therapy animal study with dose-response design
- Population
- FRRS1L knockout mouse model
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Neurotherapeutics
Why it surfaced
First preclinical gene therapy demonstration for DEE37 (no existing treatment); AAV9 intrathecal approach achieves multi-domain rescue; UTSW/Minassian group; directly actionable toward IND filing for ultra-rare pediatric neurological disorder.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.